1. A novel immune checkpoint inhibitory antibody, following the strategy of Keytruda®, Opdivo® and Tecentriq®
  2. BP1210 enhances antitumor immunity by inhibiting the exhaustion of cytotoxic T cells.

BP1210 is an innovative antibody drug that blocks the function of an immune checkpoint receptor called TIM-3, following PD-1 and PD-L1 inhibitors that are immune checkpoint inhibitors on track for drug approvals for different types or stages of cancer worldwide.

  1. Multiple ligands of TIM-3 resulting in immunosuppression

BP1210 is a humanized, anti-TIM-3 antibody that is designed to simultaneously bind to two distinct domains of TIM-3. TIM-3 has multiple ligands including phosphatidylserine (PS) and galectin-9 (Gal-9) that bind to different regions and distinctively deactivate the function of immune cells involved in tumor immunity. However, anti-TIM-3 antibodies so far in clinical development only have the capacity to interfere with PS binding but not Gal-9 binding.

  1. BP1210 biparatopic antibody (3D structure)

BP1210 is an Fc-engineered, biparatopic antibody designed to block the interaction of the multiple ligands on TIM-3. The bivalent binding to a single molecule of TIM-3 also confers high affinity and specificity to the target on the antibody, thereby allowing BP1210 to effectively abrogate the suppression of T cell cytotoxicity. BP1210 in combination with other suppressive immune pathways such as PD-1/PD-L1, is a key strategy to enhance the anti-tumor cytotoxic potential of immunotherapy.

Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity. SITC 2021